Ubs Group Ag Foghorn Therapeutics Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 7,691 shares of FHTX stock, worth $62,066. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,691

Previous 20,374 62.25%

Holding current value

$62,066

Previous $136,000 67.65%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$5.05 - $8.0 $64,049 - $101,464	-12,683 Reduced 62.25%	7,691 $44,000
Q1 2024 May 13, 2024	SELL	$2.82 - $7.94 $8,479 - $23,875	-3,007 Reduced 12.86%	20,374 $136,000
Q4 2023 Feb 09, 2024	BUY	$2.94 - $6.76 $38,058 - $87,508	12,945 Added 124.04%	23,381 $150,000
Q3 2023 Nov 09, 2023	SELL	$5.0 - $9.87 $9,475 - $18,703	-1,895 Reduced 15.37%	10,436 $52,000
Q2 2023 Aug 11, 2023	BUY	$5.37 - $8.84 $25,088 - $41,300	4,672 Added 61.0%	12,331 $86,000
Q1 2023 May 12, 2023	BUY	$4.66 - $8.99 $12,171 - $23,481	2,612 Added 51.75%	7,659 $47,000
Q4 2022 Feb 08, 2023	BUY	$5.44 - $9.46 $27,455 - $47,744	5,047 New	5,047 $32,000
Q2 2022 Aug 10, 2022	SELL	$8.48 - $16.84 $24,787 - $49,223	-2,923 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$8.87 - $22.1 $35,213 - $87,737	-3,970 Reduced 57.59%	2,923 $45,000
Q4 2021 Feb 14, 2022	BUY	$10.79 - $22.87 $74,375 - $157,642	6,893 New	6,893 $158,000
Q2 2021 Aug 13, 2021	SELL	$9.32 - $13.26 $19,907 - $28,323	-2,136 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$11.8 - $23.11 $1,321 - $2,588	-112 Reduced 4.98%	2,136 $28,000
Q4 2020 Feb 11, 2021	BUY	$15.12 - $25.88 $33,989 - $58,178	2,248 New	2,248 $46,000

Others Institutions Holding FHTX

# of Institutions

Shares Held

32.7M

Call Options Held

Put Options Held

1.8K

View Full List

About Foghorn Therapeutics Inc.

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $336M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

More about FHTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account